Glioblastomas are notoriously insensitive to radiation and genotoxic drugs. Paradoxically, the p53 gene is structurally intact in the majority (-75%) of ttiese tumors. Resistance to genotoxic modalities in p53-intact gliomas has been attributed to attenuation of p53 functions by other mutations within a p53 signaling axis that includes CDKN2A(p14^'^), MDM2 and ATM. In preliminary studies, we have generated an alternative and potentially actionable resolution to the p53 paradox. Put briefly, we have shown that the gliogenic transcription factor 0LIG2 suppresses p53-mediated responses to genotoxic damage in glioblastoma cells. Against this backdrop, the broad objective of studies proposed in this SPORE project is to use clinical materials to test the hypothesis that small molecule inhibitors of OLIG2 could serve as targeted therapeutics for glioblastoma - either as stand alone modalities or (more likely) as adjuvants to radiotherapy and genotoxic drugs. This hypothesis makes four testable predictions: Our first specific aim is to test the prediction that current standard of care (radiation and Temozolomide) actually enriches for OLIG2-positive cells within p53-positive glioblastomas. Our second specific aim is to test the prediction that one current class of radiosensifizing drugs - the HDAC inhibitors - actually work by suppressing 0L1G2 expression in cancer patients. Our third specific aim is to test the prediction that genetic suppression of 0L1G2 can sensitize p53-positive human gliomas to radiotherapy in vivo. Our fourth specific aim is to test the prediction that shRNA-mediated knockdown of genes essential to 0L1G2 function (e.g. HDACs) will be synthetic lethal to irradiation in p53 positive gliomas. The basic scientist on this project (CD Stiles, PhD) is a molecular biologist and the clinical investigator (JS Loeffler) is a radiation oncologist. Dr Stiles and his students initially cloned the OLIG genes and defined their biological functions in brain development and malignant glioma. Dr Loeffier is a leader in the field of brain tumor irradiation with a special interest in glioblastomas. Together they have the skill sets required for successful completion ofthe study plan. The work they propose will be supported by dedicated SPORE core facilities for Pathology and Biostatistics. If the work described here supports the view that 0LIG2 is a viable target for glioma therapeutics, clinical trials of 0L1G2 antagonists (e.g. HDAC inhibitors) as an adjuvant to radiotherapy can be initiated within a five-year period of time.

Public Health Relevance

Glioblastomas are the third leading cause of cancer-related death among middle-aged men and the fourth leading cause of death for women between 15-34 years of age. In the fullness of time, the worl

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA165962-01A1
Application #
8588494
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (M1))
Project Start
2013-09-19
Project End
2018-07-31
Budget Start
2013-09-19
Budget End
2014-07-31
Support Year
1
Fiscal Year
2013
Total Cost
$288,558
Indirect Cost
$76,115
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Peterson, Teresa E; Kirkpatrick, Nathaniel D; Huang, Yuhui et al. (2016) Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. Proc Natl Acad Sci U S A 113:4470-5
Kloepper, Jonas; Riedemann, Lars; Amoozgar, Zohreh et al. (2016) Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Proc Natl Acad Sci U S A 113:4476-81
Flavahan, William A; Drier, Yotam; Liau, Brian B et al. (2016) Insulator dysfunction and oncogene activation in IDH mutant gliomas. Nature 529:110-4
Curry Jr, William T; Gorrepati, Ramana; Piesche, Matthias et al. (2016) Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma. Clin Cancer Res 22:2885-96
Stevens, Mark M; Maire, Cecile L; Chou, Nigel et al. (2016) Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate. Nat Biotechnol 34:1161-1167
Verreault, Maite; Schmitt, Charlotte; Goldwirt, Lauriane et al. (2016) Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas. Clin Cancer Res 22:1185-96
Ni, Jing; Ramkissoon, Shakti H; Xie, Shaozhen et al. (2016) Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. Nat Med 22:723-6
Tateishi, Kensuke; Iafrate, A John; Ho, Quan et al. (2016) Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma. Clin Cancer Res 22:4452-65
Cizmecioglu, Onur; Ni, Jing; Xie, Shaozhen et al. (2016) Rac1-mediated membrane raft localization of PI3K/p110β is required for its activation by GPCRs or PTEN loss. Elife 5:
Fathi, Amir T; Nahed, Brian V; Wander, Seth A et al. (2016) Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma. Oncologist 21:214-9

Showing the most recent 10 out of 44 publications